These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38374699)
1. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies. Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. Sung HH; Kim H; Kim R; Kim CK; Kwon GY; Park W; Song W; Jeong BC; Park SH Investig Clin Urol; 2022 Mar; 63(2):168-174. PubMed ID: 35244990 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE; Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder. Kim H; Jeong BC; Hong J; Kwon GY; Kim CK; Park W; Pyo H; Song W; Sung HH; Hong JY; Park SH Cancer Res Treat; 2023 Apr; 55(2):636-642. PubMed ID: 36228654 [TBL] [Abstract][Full Text] [Related]
7. An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer. Feng YH; Shen KH; Huang KH; Tzeng WS; Li CF; Lin KL Clin Genitourin Cancer; 2016 Feb; 14(1):e67-74. PubMed ID: 26428609 [TBL] [Abstract][Full Text] [Related]
8. Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study. Luo C; Luo S; Wusimanjiang W; Wang Z; Liu P; Wang B; Yuan D; Lin H; Xu A; Deng N; Wu K; Zhu X; Xu P; Chen J; Huang B Clin Transl Oncol; 2024 Jul; 26(7):1759-1767. PubMed ID: 38472556 [TBL] [Abstract][Full Text] [Related]
9. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506 [TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794 [TBL] [Abstract][Full Text] [Related]
11. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470 [TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility. Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832 [TBL] [Abstract][Full Text] [Related]
14. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial. Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064 [TBL] [Abstract][Full Text] [Related]
15. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute. Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111 [TBL] [Abstract][Full Text] [Related]
18. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183 [TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. Meleis L; Moore R; Inman BA; Harrison MR J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469 [TBL] [Abstract][Full Text] [Related]
20. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]